Wednesday, July 8, 2026

Patent intelligence · US

US 11524939

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

granted A61KA61K9/0053A61K9/145
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 28
Patent details — US 11524939

Quick answer

US 11524939 (Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid) is held by Akebia Therapeutics, Inc.. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K9/0053, A61K9/145

More from Akebia Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419877

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Akebia Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Expires Jan 25, 2044

    granted
  3. US 11857543

    Compositions and methods for treating anemia

    Akebia Therapeutics, Inc. · Expires Dec 28, 2043

    granted
  4. US 11844756

    Compositions and methods for treating anemia

    Akebia Therapeutics, Inc. · Expires Dec 14, 2043

    granted
  5. US 11690836

    Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

    Akebia Therapeutics, Inc. · Expires Jun 29, 2043

    granted
  6. US 11426393

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Expires Aug 25, 2042

    granted
  7. US 11324734

    Compositions and methods for treating anemia

    Akebia Therapeutics, Inc. · Expires May 5, 2042

    granted

Frequently asked questions

What is US patent 11524939?

US 11524939 (Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid) is held by Akebia Therapeutics, Inc.. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11524939?

Akebia Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.

When does US 11524939 expire?

Our index shows an expiration date of Dec 8, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.